This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Syros Pharmaceuticals’s 8K filing here.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
Recommended Stories
- Five stocks we like better than Syros Pharmaceuticals
- ESG Stocks, What Investors Should Know
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- Technology Stocks Explained: Here’s What to Know About Tech
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Investing in Commodities: What Are They? How to Invest in Them
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
